These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 10435390)
1. Selective attenuation of the antinociceptive effects of mu opioids by the putative dopamine D3 agonist 7-OH-DPAT. Cook CD; Rodefer JS; Picker MJ Psychopharmacology (Berl); 1999 Jun; 144(3):239-47. PubMed ID: 10435390 [TBL] [Abstract][Full Text] [Related]
2. Modulatory effects of dopamine D3/2 agonists on kappa opioid-induced antinociception and diuresis in the rat. Cook CD; Barrett AC; Syvanthong C; Picker MJ Psychopharmacology (Berl); 2000 Sep; 152(1):14-23. PubMed ID: 11041311 [TBL] [Abstract][Full Text] [Related]
3. The dopamine D3/2 agonist 7-OH-DPAT attenuates the development of morphine tolerance but not physical dependence in rats. Cook CD; Barrett AC; Syvanthong C; Picker MJ Psychopharmacology (Berl); 2000 Sep; 152(1):93-104. PubMed ID: 11041321 [TBL] [Abstract][Full Text] [Related]
4. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; turning behaviour. Koshikawa N; Kitamura M; Kobayashi M; Cools AR Eur J Pharmacol; 1996 Jul; 308(3):235-41. PubMed ID: 8858293 [TBL] [Abstract][Full Text] [Related]
5. Dopaminergic activity and the discriminative stimulus effects of mu opioids in pigeons: importance of training dose and attenuation by the D3 agonist (+/-)-7-OH-DPAT. Cook CD; Picker MJ Psychopharmacology (Berl); 1998 Mar; 136(1):59-69. PubMed ID: 9537683 [TBL] [Abstract][Full Text] [Related]
6. D2 and D1 dopaminergic activity of 7-OH-DPAT. Sethy VH; Ellerbrock BR; Fici GJ; Wu H Brain Res; 1996 Sep; 733(1):41-5. PubMed ID: 8891246 [TBL] [Abstract][Full Text] [Related]
7. Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Kurashima M; Yamada K; Nagashima M; Shirakawa K; Furukawa T Pharmacol Biochem Behav; 1995 Nov; 52(3):503-8. PubMed ID: 8545466 [TBL] [Abstract][Full Text] [Related]
8. Effects of dopaminergic agents on antinociception in formalin test. Zarrindast MR; Nassiri-Rad S; Pazouki M Gen Pharmacol; 1999 Apr; 32(4):517-22. PubMed ID: 10323495 [TBL] [Abstract][Full Text] [Related]
9. Supraspinal D2 receptor involved in antinociception induced by l-tetrahydropalmatine. Hu JY; Jin GZ Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):715-9. PubMed ID: 10678104 [TBL] [Abstract][Full Text] [Related]
10. Modulation of the discriminative stimulus effects of mu opioid agonists in rats: II. Effects of dopamine D2/3 agonists. Cook CD; Beardsley PM Behav Pharmacol; 2004 Feb; 15(1):75-83. PubMed ID: 15075629 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of putative dopamine D3 receptor agonists, 7-OH-DPAT and quinpirole, on prolactin secretion in rats. Kurashima M; Domae M; Inoue T; Nagashima M; Yamada K; Shirakawa K; Furukawa T Pharmacol Biochem Behav; 1996 Feb; 53(2):379-83. PubMed ID: 8808147 [TBL] [Abstract][Full Text] [Related]
12. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Depoortere R; Perrault G; Sanger DJ Psychopharmacology (Berl); 1996 Apr; 124(3):231-40. PubMed ID: 8740044 [TBL] [Abstract][Full Text] [Related]
13. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; jaw movements. Koshikawa N; Miwa Y; Adachi K; Kobayashi M; Cools AR Eur J Pharmacol; 1996 Jul; 308(3):227-34. PubMed ID: 8858292 [TBL] [Abstract][Full Text] [Related]
15. Decreased locomotor activity after microinjection of dopamine D2/D3 receptor agonists and antagonists into lobule 9/10 of the cerebellum: a D3 receptor mediated effect? Boulay D; Depoortere R; Perrault G; Sanger DJ Prog Neuropsychopharmacol Biol Psychiatry; 2000 Jan; 24(1):39-49. PubMed ID: 10659982 [TBL] [Abstract][Full Text] [Related]
16. Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors. Starr MS; Starr BS Eur J Pharmacol; 1995 Apr; 277(2-3):151-8. PubMed ID: 7493603 [TBL] [Abstract][Full Text] [Related]
18. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181 [TBL] [Abstract][Full Text] [Related]
19. 5-hydroxytryptamine (HT)1A receptors and the tail-flick response. II. High efficacy 5-HT1A agonists attenuate morphine-induced antinociception in mice in a competitive-like manner. Millan MJ; Colpaert FC J Pharmacol Exp Ther; 1991 Mar; 256(3):983-92. PubMed ID: 1672380 [TBL] [Abstract][Full Text] [Related]
20. Analysis of D2 and D3 receptor-selective ligands in rats trained to discriminate cocaine from saline. Garner KJ; Baker LE Pharmacol Biochem Behav; 1999 Oct; 64(2):373-8. PubMed ID: 10515316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]